Table 4.

CD8+ expansions in age-matched controls and multiple myeloma patients

Age-matched controlsPatients with MM4-150
No. subjects in study 27 22  
No. subjects with CD8+ expansions4-151 16 21  
Total no. CD8+ expansions4-151 23 71  
Mean no. CD8+ expansions per positive subject4-151 1.4 3.4  
No. subjects with CD8+ expansions predicted to be detectable by Southern blot 13  
Total no. CD8+ expansions predicted to be detectable by Southern blot 25 
No. CD8+ expansions predicted to be detectable by Southern blot per positive subject 1.3 1.9 
Total no. CD8+expansions4-151,4-153 20 35 
Age-matched controlsPatients with MM4-150
No. subjects in study 27 22  
No. subjects with CD8+ expansions4-151 16 21  
Total no. CD8+ expansions4-151 23 71  
Mean no. CD8+ expansions per positive subject4-151 1.4 3.4  
No. subjects with CD8+ expansions predicted to be detectable by Southern blot 13  
Total no. CD8+ expansions predicted to be detectable by Southern blot 25 
No. CD8+ expansions predicted to be detectable by Southern blot per positive subject 1.3 1.9 
Total no. CD8+expansions4-151,4-153 20 35 

Data were calculated as a function of total CD3+cells, except where noted otherwise.

MM indicates multiple myeloma.

F4-150

Reanalyzed data of 22 patients with MM from previous publication.5 

F4-151

After gating for CD8+CD3+ T cells, expanded populations were those calculated as a function of total CD3+ cells and that present at 3 SD or more above the mean percentage of Vβ+CD8+ cells of the age-matched controls.

The size of monoclonal Vβ+populations (predicted to be detectable by Southern blot) was estimated by subtracting the mean values for the particular Vβ from the percentage of CD8+CD3+ T cells, calculated as above.

F4-153

Calculated as a function of total CD8+ cells.

Close Modal

or Create an Account

Close Modal
Close Modal